Bbiologics are an emerging treatment option for COPD. Recent biologic agent approval by NICE wa but how will the system respond to meet this implementation challenge? This session will explore and discuss this for respiratory care.

Attendees will:

• Gain practical and strategic oversight of how biologic agents for COPD can be utilised for patient benefit
• Discuss optimal models of care delivery and the vital role of pharmacy